Navigation Links
Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
Date:8/29/2007

nology is based on the synthesis of conformationally sensitive peptides (chains of amino acids that are smaller than proteins) which are created to target specific protein shapes associated with various diseases. The interaction of the target protein with Adlyfe's proprietary peptides produces a conformational change that transduces a fluorescent signal. Further amplification of the signal is generated as additional ligands undergo conformational changes. This is the basis for the tests' sensitivity and ability to detect very low amyloid protein levels before symptoms occur.

"The publication of this study validates the utility and sensitivity of our MPD assay in detecting misfolded proteins in TSE, even at low levels," said Chief Executive Officer Alan S. Rudolph, Ph.D. "We believe our test meets the dual diagnostic demands of confirmatory testing in symptomatic subjects suspected of having the disease and as a screening test to identify infection in its earliest phases. Our unique diagnostic approach and technology is applicable to a number of neurological diseases associated with protein buildup in tissues such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease."

About Adlyfe

Adlyfe Inc. was established early in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain and amyloid diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease, Huntington's disease, systemic amyloidosis, diabetes and other diseases.

The Company's novel technology is based on the synthesis of small peptide, or Pronucleon(TM) ligands, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid
'/>"/>

SOURCE Adlyfe
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... , Sept. 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has granted orphan drug ... hypertension. "The FDA Office of Orphan ... from sponsors to identify and designate drug candidates that ... evaluation and development of such products," said Craig ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... SUNNYVALE, Calif., July 7, 2011 Cepheid (Nasdaq: ... for its 2011 second quarter ended June 30, 2011, on ... The company will host a management presentation at ... discuss the results.  To access the live webcast, please visit ...
... just three weeks after hearing oral argument, the First District ... judgment against Johnson & Johnson (NYSE: JNJ ) ... death case involving their Duragesic® fentanyl pain patch. ... in DiCosolo v. ALZA Corp, et al ., obtained ...
Cached Medicine Technology:Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 3
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
(Date:9/2/2014)... By Steven Reinberg ... (HealthDay News) -- Stimulant medications -- such as Adderall, ... (ADHD) in children, won,t stunt their growth, a new ... final height as adults," said study researcher Dr. Slavica ... Clinic in Rochester, Minn. Katusic noted that results ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 ... loss by blocking a certain nerve linked to appetite and ... patients. Using electric impulses to block the vagus nerve, ... suppress feelings of hunger. And, they did, just not to ... the nerve that connects the brain to the gut can ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Drinking and marijuana may ... a new study suggests. Researchers analyzed 2007 to ... school seniors who said they had used alcohol or ... drinking alcohol was associated with more unsafe driving, damage ... about actions while under the influence of alcohol, especially ...
Breaking Medicine News(10 mins):Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2
... be making us hungrier, so we eat more, which in ... Yang and his colleagues at the Lawson Health Research Institute ... tissue can reproduce a hormone that stimulates fat cell production. ... way we think about and treat abdominal obesity. , Yang ...
... 16 Skanska USA Building Inc.,announced today that ... service the,growing Indiana construction markets. The announcement was ... Midwest operations., "Indiana is a strong construction ... "Skanska is an industry leader and after,working in ...
... Facing the ... Healthcare Industry, ... with U.S. News & World Report,hosted an exclusive panel discussion ... National Press Club in Washington, D.C.,The event, attended by Congressional ...
... with a faulty breast cancer gene could be at ... genes, according to research published this month in the ... University of Pennsylvania School of Medicine join an international ... 10,000 women carrying a BRCA1 or BRCA2 mutation for ...
... the source should lead to more effective vaccines, researchers say ... strains of virus that produce seasonal flu epidemics start in ... of the world, researchers report. , And by focusing on ... to improve their forecast of seasonal flu strains and develop ...
... Ala. - New clinical data showed some cancer patients ... AME-133v, said a researcher at the University of Alabama ... 15th during the 2008 annual meeting of the American ... 1 clinical trial data showed AME-133v had a potent ...
Cached Medicine News:Health News:Your belly fat could be making you hungrier 2Health News:Skanska Opens Indianapolis Office 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3Health News:Breast cancer risk amplified by additional genes in combo with BRCA mutation 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: